CD19 and cancer: In the first decade, major emphasis was placed on transferring concepts and theories into clinical practice, including developing the 2nd and 3rd generation of CAR-T cells (19), establishing preclinical studies in different kinds of cancers (20) and receiving FDA approval for the first time for CAR-T cells targeting CD19 (10, 11); thus, relatively few studies were published in this interval.